Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Patient-based surveys will be conducted to evaluate the drivers of medication adherence in
patients treated with either 5-alpha-reductase inhibitor (5ARI) therapy, alpha-blocker (AB)
therapy, or combination therapy for enlarged prostate (EP). Adherence with EP therapy will be
evaluated. The researchers believe that the majority of participants will report that they
are compliant with therapy. The data source is a cross-sectional patient survey administered
at one time point.